Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN67,9367,96-0,73
Msft7,63
Nokia4,3854,451,06
IBM-0,89
Mercedes-Benz Group AG52,6252,65-2,73
PFE-1,97
02.05.2025 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 01.05.2025
Hikma Pharma (HIK.L, London)
Závěr k 1.5.2025 Změna (%) Změna (GBP) Objem obchodů (GBP)
19,99 0,71 0,14 2 495 907
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 02.05.2025
Popis společnosti
Obecné informace
Název společnostiHikma Pharmaceuticals Plc
TickerHIK
Kmenové akcie:Ordinary Shares
RICHIK.L
ISINGB00B0LCW083
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.12.2024
Počet zaměstnanců k 31.12.2024 9 308
Akcie v oběhu k 31.12.2024 221 886 453
MěnaUSD
Kontaktní informace
Ulice1 New Burlington Place
MěstoLONDON
PSČW1S 2HR
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon442 073 992 760
Fax442073992761

Business Summary: Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Hikma Pharmaceuticals Plc revenues increased 10% to $3.16B. Net income increased 89% to $359M. Revenues reflect Injectable Pharmaceuticals segment increase of 8% to $1.3B, Generic Pharmaceuticals segment increase of 9% to $1.03B, Branded Pharmaceuticals segment increase of 8% to $769M, United States segment increase of 9% to $1.91B, Middle East and North Africa segment increase of 8% to $985M.
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSDrugs and Druggists' Sundries Merchant Wholesalers
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Drugs and Druggists' Sundries Merchant Wholesalers
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Drug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 02.05.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Executive Chairman of the BoardSaid Darwazah6601.09.202301.07.2007
Chief Executive Officer, Executive DirectorRiad Mishlawi-01.09.202301.01.2011
Executive Vice Chairman of the Board, President of MENAMazen Darwazah-08.09.2005
Chief Financial OfficerKhalid Nabilsi-01.01.2008
President - GenericsHafrun Fridriksdottir-15.04.202415.04.2024
President - InjectablesBill Larkins-01.09.202301.09.2023
Chief People OfficerHussein Arkhagha-01.01.2013
Executive Vice President - Strategic Planning and Global AffairsSusan Ringdal-
Executive Vice President - Corporate Development and M and ABassam Wael Roshdi Kanaan59
Senior Vice President - Corporate Quality Compliance and Health and SafetyJulie Hill-